Lexaria Bioscience Corp.

Third pharmaceutical company relationship entered    Kelowna, British Columbia – November 4, 2026 – TheNewswire - Lexaria Bioscience Corp. (Nasdaq: LEXX) (the “ Company ” or “ Lexaria ”), a global innovator in drug delivery platforms, announces that it has entered into an Agreement with an unnamed pharmaceutical company (“ PharmCo ”) to investigate Lexaria's DehydraTECH technology with one or more proprietary PharmCo molecules.

New patents awarded in the US, Canada, and Europe  IP protection for treatments for Epilepsy, Diabetes, and Hypertension

Kelowna, BC – October 21, 2026 – TheNewswire - Lexaria Bioscience Corp. (NASDAQ:LEXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, reports that full enrollment has been reached and dosing continues on schedule with Human Pilot Study #7 (GLP-1-H26-7) which is evaluating two oral DehydraTECH-semaglutide (“DHT-sema”) compositions against Novo's®  commercially available Wegovy® tablets, over a 5-week duration (the “ Study ”).   The final Study arm was fully enrolled and began dosing, as scheduled, in early October. This final group is expected to complete their dosing in mid-November, to be followed by completion of all laboratory sample analyses and reporting.

Results highlighted by a 566% improvement in brain absorption of DehydraTECH-CBD KELOWNA, BC / ACCESS Newswire / October 15, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to provide the following results from animal study GLP-1-A26-1 (the "Study") that evaluated a number of formulation enhancements using both DehydraTECH-CBD ("DHT-CBD") compositions and DehydraTECH-semaglutide ("DHT-SEMA") glucagon-like peptide-1 ("GLP-1") compositions to explore the potential for additional improved performance, as well as stake new intellectual property ("IP") claims. Lexaria has already filed 3 new patent applications related to the formulations evaluated in this Study to protect this new IP.